UPADACITINIB

Search structure
Trade Names:
Synonyms:
Status: Approved (2019)
Entry Type: Small molecule
Molecule Category: UNKNOWN
ATC: L04AA44
UNII: 4RA0KN46E0

Structure
InChI Key WYQFJHHDOKWSHR-MNOVXSKESA-N
Smile CC[C@@H]1CN(C(=O)NCC(F)(F)F)C[C@@H]1c1cnc2cnc3[nH]ccc3n12
InChI
InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C17H19F3N6O
Molecular Weight 380.37
AlogP 2.91
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 2.0
Number of Rotational Bond 3.0
Polar Surface Area 78.32
Molecular species NEUTRAL
Aromatic Rings 3.0
Heavy Atoms 27.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Janus Kinase (JAK) inhibitor FDA
Primary Target
Janus kinase 1
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase JakA family
- 8-608 - 1 -
Enzyme Kinase Protein Kinase TK protein kinase group Tyrosine protein kinase JakB family
- 8-608 - 1 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Arthritis, Rheumatoid 4 D001172 FDA
Arthritis, Psoriatic 3 D015535 ClinicalTrials
Spondylitis, Ankylosing 3 D013167 ClinicalTrials
Dermatitis, Atopic 3 D003876 ClinicalTrials
Giant Cell Arteritis 3 D013700 ClinicalTrials
Crohn Disease 3 D003424 ClinicalTrials
Colitis, Ulcerative 3 D003093 ClinicalTrials
Vitiligo 2 D014820 ClinicalTrials
Lupus Erythematosus, Systemic 2 D008180 ClinicalTrials
Hidradenitis Suppurativa 2 D017497 ClinicalTrials
Arthritis, Juvenile 1 D001171 ClinicalTrials

Cross References

Resources Reference
CAS NUMBER 1310726-60-3
ChEMBL CHEMBL3622821
DrugBank DB15091
DrugCentral 5346
FDA SRS 4RA0KN46E0
Guide to Pharmacology 9246
PubChem 58557659
SureChEMBL SCHEMBL9991056
CONTENTS